Liver X receptor marks the spot
Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in metastatic melanoma.1
The group, led by The Rockefeller University assistant professor Sohail Tavazoie, came upon the nuclear hormone receptor as a melanoma target while studying the effect of apolipoprotein E (APOE) on cancer metastasis.
APOE is the protein component of cholesterol-carrying lipoprotein particles.
In 2012, Tavazoie's team discovered that Apoe produced by noncancerous tissue combats melanoma vascularization and metastasis.2
"In our previous paper we used an unbiased approach to show